Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2016.4510
Abstract: Importance The Canadian Cancer Trials Group study HN.6 is the largest randomized clinical trial to date comparing the concurrent administration of anti–epidermal growth factor receptor (EGFR) monoclonal antibodies with radiotherapy (RT) to standard chemoradiotherapy in… read more here.
Keywords: clinical trial; pfs; trial; fractionation ... See more keywords
Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2017.0324
Abstract: Importance Although oral metronomic chemotherapy is often used in progressive pediatric solid malignant tumors, a literature review reveals that only small single-arm retrospective or phase 1 and 2 studies have been performed. Skepticism abounds because… read more here.
Keywords: chemotherapy; pfs; trial; metronomic chemotherapy ... See more keywords
Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors.
Sign Up to like & getrecommendations! Published in 2018 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2017.3983
Abstract: Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors To the Editor In the trial conducted by Pramanik and colleagues1 for treating progressive pediatric solid malignant tumors, the primary end point was progression-free survival (PFS).… read more here.
Keywords: chemotherapy; pfs; metronomic chemotherapy; solid malignant ... See more keywords
Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2019.1847
Abstract: Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. Objective To determine whether adding… read more here.
Keywords: pfs; egfr mutant; trial; erlotinib ... See more keywords
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25783
Abstract: Immunochemotherapy followed by autologous transplant (ASCT) in CALGB/Alliance 59909 achieved a median progression‐free survival (PFS) in mantle cell lymphoma (MCL) of 5 years, but late recurrences occurred. We evaluated tolerability and efficacy of adding post‐transplant bortezomib… read more here.
Keywords: pfs; calgb alliance; mantle cell; cell ... See more keywords
Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer medicine"
DOI: 10.1002/cam4.4628
Abstract: OBJECTIVE To evaluate the efficacy and outcome of transarterial embolization (TAE) plus octreotide long-acting repeatable (LAR) on patients with low-to-intermediate neuroendocrine tumor liver metastases (NETLM). METHODS One hundred and sixteen patients with G1/G2 NETLM treated… read more here.
Keywords: tumor; response; neuroendocrine tumor; transarterial embolization ... See more keywords
Validation of NRG Oncology's prognostic nomograms for oropharyngeal cancer in the Veterans Affairs database.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34141
Abstract: BACKGROUND To test whether nomograms developed by NRG Oncology for oropharyngeal squamous cell carcinoma (OPSCC) patients could be validated in an independent population-based sample. METHODS The authors tested nomograms for estimating progression-free survival (PFS) and… read more here.
Keywords: cancer; validation; nrg oncology; complete cases ... See more keywords
UPFRONT AHSCT IN NON HODGKIN LYMPHOMA‐BETTER OUTCOME?
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.108_2631
Abstract: and Clinical Study registry NIHIL (govTrial no: NCT03199066). Basic characteristics are summarized in Table 1. The clinical outcomes of DA-EPOCH-R cohort were compared to 117 pts treated with RCHOP regimen from 2 centres where intensification… read more here.
Keywords: pfs; hodgkin lymphoma; ahsct non; lymphoma better ... See more keywords
Relationship between venetoclax exposure, rituximab coadministration, and progression‐free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2373
Abstract: Venetoclax is indicated at a dosage of 400 mg daily (QD) for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion who have received at least 1 prior therapy. Ongoing trials are… read more here.
Keywords: pfs; venetoclax; rituximab coadministration; effect ... See more keywords
Prognostic significance of monoclonal gammopathy in diffuse large B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.2685
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). Although introduction of rituximab in the upfront treatment of DLBCL was followed by a major improvement in response and survival, up… read more here.
Keywords: pfs; igg iga; dlbcl; presence ... See more keywords
Prognostic value of lesion dissemination in ABVD-treated, iPET-negative cHL patients: A radio-genomic study.
Sign Up to like & getrecommendations! Published in 2022 at "Hematological oncology"
DOI: 10.1002/hon.3025
Abstract: We evaluated the prognostic role of the largest distance between two lesions (Dmax), defined by positron emission tomography (PET) in a retrospective cohort of newly diagnosed classical Hodgkin Lymphoma (cHL) patients. We also explored the… read more here.
Keywords: chl patients; chl; pfs; gene expression ... See more keywords